Background: Heart failure is the leading cause of morbidity and mortality and it affects multiple organs and systems. Liver failure and dysfunction is one of the common and major complications of HF. Angiotensin Receptor Neprilysin Inhibitor (ARNI) signifies the paradigm shift in the treatment of HF and it is shown to reduce the mortality and morbidity in Heart failure (HF) patients. But worries about the possible hepatotoxicity of ARNI have been raised, particularly in patients with pre-existing liver disease. Hence this present study is undertaken to assess the efficacy of ARNI on measures of liver function in patients with HFrEF compared to conventional therapy.
Materials and Methods: This is a cross-sectional study. Around 65 patients with heart failure with reduced ejection fraction were recruited after obtaining informed consent and institutional ethical clearance. Patients with symptomatic hypotension, estimated glomerular filtration rate < 30 mL/min/1.73 m², history of serious side effects during treatment with ACEI or ARB, patients with aspartate aminotransferase (AST) or alanine aminotransferase (ALT) exceeding twice the upper limit of normal, history of hepatic encephalopathy, oesophageal varices, or portacaval shunt were excluded from this study.
Results: In the present study, it was shown that total bilirubin, AST, ALT, ALP, and creatinine mean values are lower in the ARNI group compared to those who are not on ARNI. MELD-XI score was reduced in patients with ARNI treatment and it was found to be statistically significant (p = 0.04).
Conclusion: Liver parameters and MELD-XI score were found to be better in HF patients with ARNI treatment when compared with patients without ARNI treatment. In conclusion, ARNI treatment is found to be beneficial for heart as well as liver parameters.
Keywords: Heart failure, ARNI, liver function, MELD-XI score, hepatotoxicity, HFrEF.
How to cite this article: Gopan AGP, Rajasekaran M, Rajasekhar S, Aamir SA, Ananthakumar PK. Liver function in patients with heart failure on ARNI compared to those who are not on ARNI. Int J Drug Deliv Technol. 2026;16(6s): 65-67; DOI: 10.25258/ijddt.16.6s.7
Source of support: Nil.
Conflict of interest: None